# Omega-3 Fatty Acid Treatment in Multiple Sclerosis

> **NCT00360906** · PHASE2,PHASE3 · COMPLETED · sponsor: **Haukeland University Hospital** · enrollment: 100 (—)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Triomar™ (omega-3 fatty acids)

## Key facts

- **NCT ID:** NCT00360906
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2008-07
- **Target enrollment:** 100 (—)
- **Last updated:** 2006-08-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00360906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00360906, "Omega-3 Fatty Acid Treatment in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00360906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*